Crohn's Disease Treatment Options
Below is a summary of treatment options for Crohn's disease (CD).1-5
| Treatment |
Administration |
Uses |
| Aminosalicylates |
Oral
Enema
Suppository |
Commonly prescribed for mild to moderate disease |
| Corticosteroids |
Oral
Enema
Rectal foam
Suppository
IV |
Commonly prescribed for moderate to severe disease; For mild to moderate disease of the ileocecal region (budesonide only) |
| Antibiotics |
Oral
IV |
Commonly prescribed for mild to moderate disease. Induction of remission in patients with mild to moderate disease; Perianal, fistulizing, or refractory disease; Postsurgery to prevent flare-ups |
| Immunosuppressants |
Oral
IM and SC
(methotrexate only) |
Commonly prescribed for moderate to severe disease; Maintenance of remission; Reduction of steroid use |
Biologic
CIMZIA®
(certolizumab pegol) |
Subcutaneous injection |
FDA approved and indicated for reducing signs and symptoms of disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy |
Biologic
HUMIRA®
(adalimumab) |
Subcutaneous injection |
FDA approved and indicated for reducing signs and symptoms, and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy; Reducing signs and symptoms, and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab |
Biologic
Remicade®
(infliximab) |
IV infusion |
FDA approved and indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy; reduction of the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure |
Biologic
TYSABRI®
(natalizumab) |
IV infusion |
FDA approved and indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-alpha |
Note: Chart does not imply comparable safety or efficacy.
References:
- Hanauer SB, Sandborn W; Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines: management of Crohn's disease in adults. Am J Gastroenterol. 2001;96:635-643.
- CIMZIA [prescribing information]. Smyrna, GA: UCB, Inc.; 2009.
- Humira [package insert]. Chicago, IL: Abbott Laboratories; 2009.
- Remicade [package insert]. Malvern, PA: Centocor, Inc; 2009.
- Tysabri [package insert]. San Francisco, CA: Elan Pharmaceuticals, Inc.; 2008
